Ovarian Cancer Clinical Trials
Ovarian cancer clinical trials provide new ways to prevent, diagnose and treat ovarian cancer. To accomplish this, eligible patients who agree to participate are given opportunities to try promising new drugs, treatment approaches or advances in new areas, such as gene therapy. As a pioneer in cancer research, Moffitt Cancer Center is the only National Cancer Institute-designated Comprehensive Cancer Center based in Florida. We offer our patients outstanding treatment options, including access to a wide range of innovative clinical trials for ovarian and other types of cancer.
Choosing a Clinical Trial to Treat Ovarian Cancer
If a physician at Moffitt suggests a clinical trial as a treatment option, the physician will help the patient make an educated decision on whether it is right for her. This process, which is known as informed consent, involves learning the details of the trial and gaining a full understanding of what it will entail. For example, if a patient is considering joining one of our ovarian cancer clinical trials, she will be provided with information on:
- The purpose of the trial
- The procedures involved, including the frequency and timing of testing, physician visits and any required hospitalization
- How the treatment under study might help her
- The risks and benefits of participation
- Possible side effects
- All treatment options that are currently available to her
- What she can expect if she does or does not participate
- How her participation might affect her everyday life
- Her right to leave the study and pursue other treatments at any time, even after signing an informed consent form
Clinical trials offer patients the opportunity to be among the first to benefit from new drugs and treatment approaches. Additionally, they are vital to the advancement of the medical field. These research studies provide the evidence physicians need to improve the care of cancer patients. In fact, all of the effective cancer treatments that are available today are based on the results of past clinical trials.
To learn more about the ovarian cancer clinical trials being conducted by the cancer experts at Moffitt, call 1-813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form online.
-
Clinical Trials
CLINICAL TRIAL 20497
A Multicenter, Open-Label Phase 1/2 Trial Evaluating the Safety, Tolerability and Efficacy of MORAb-202, a Folate Receptor Alpha (FRA)-Targeting Antibody-Drug Conjugate (ADC) in Subjects with Selected Tumor Types
Condition: Gynecological Tumor
Intervention: E7080 (Lenvatinib); Lenvatinib (Lenvima); MORAb-202 ()
CLINICAL TRIAL 20870
Pilot Study to Assess the Efficacy of Aspirin to Improve Immunological Features of Ovarian Tumors
Condition: Gynecological Tumor
Intervention: Aspirin/Placebo (); Avastin (Bevacizumab); Bevacizumab (); Paraplatin (carboplatin); Taxol (paclitaxel); carboplatin (); paclitaxel ()
CLINICAL TRIAL 21113
A Phase I Clinical Trial of an Infusion of Autologous T Cells Genetically Engineered with a Chimeric Receptor to Target the Follicle-Stimulating Hormone Receptor in Patients with Recurrent Ovarian Cancer
Condition: Gynecological Tumor
Intervention: FSHR T-Cells (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
CLINICAL TRIAL 21589
BASECAMP-1: An Observational Study Obtaining Solid Tumor Tissue from Subjects with Primary Surgical Resection and Leukapheresis for CAR T-Cell Therapy Manufacturing
Condition: Immunotherapy
Intervention:
CLINICAL TRIAL 21899
Phase Ib Expansion Study of CX-5461 in Patients with Solid Tumours and BRCA2 and/or PALB2 Mutation
Condition: Multiple
Intervention: CX-5461 ()
CLINICAL TRIAL 22102
A Phase 1b, First-in-human, Dose Escalation and Expansion, Multicenter Study of XMT-1660 in Participants with Solid Tumors
Condition: Multiple
Intervention: XMT-1660 ()
CLINICAL TRIAL 23143
Trends and Outcomes in HIV-positive Patients Undergoing Treatment for Invasive or Preinvasive Cervical and Other Gynecologic Neoplasias
Condition: Gynecological Tumor
Intervention:
CLINICAL TRIAL 23176
A Phase 2, randomised, open label, multicentre study of an intraperitoneal alpha-emitting radionuclide therapy (Radspherin®) in patients with primary advanced high-grade serous or high-grade endometrioid epithelial ovarian, fallopian tube, or primary peritoneal cancer, with peritoneal metastasis that are homologous recombination proficient and scheduled to undergo neoadjuvant chemotherapy and interval debulking surgery
Condition: Gynecological Tumor
Intervention: Radspherin ()
CLINICAL TRIAL 23223
A Phase 3, Randomized, Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator s Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
Condition: Gynecological Tumor
Intervention: Anastrozole (); Arimadex (Anastrozole); Avutometinib (); Defactinib (VS-6063); Femara (Letrozole); Letrozole (); PEGylated Liposomal Doxorubicin (); Taxol (paclitaxel); Topotecan (); paclitaxel ()
CLINICAL TRIAL 23255
An Open-Label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of XL309 (ISM3091) as Single-Agent and Combination Therapy in Patients with Advanced Solid Tumors
Condition: Multiple
Intervention: Olaparib (Lynparza); XL309 ()
CLINICAL TRIAL 23378
A phase 1/2, first-in-human study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of AVZO-021 as a single agent and in combination therapy in patients with advanced solid tumors
Condition: Breast
Intervention: 772256 (Palbociclib); AVZO-021 (); Abemaciclib (); Faslodex (fulvestrant); Femara (Letrozole); LEE011 (Ribociclib); LY2835219 (Abemaciclib); Letrozole (); Palbociclib (); Paraplatin (carboplatin); Ribociclib (); Sacituzumab Govitecan (); carboplatin (); fulvestrant ()
CLINICAL TRIAL 23380
A Seamless Phase 1/2 Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Autologous Logic-gated Tmod CAR T Protducts in Heterozygous HLA-A*02 Adult with Recurrent Unresectable, Locally Advanced, or Metastatic Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Condition: Thoracic
Intervention: A2B543 (); A2B694 (); IL-2 (Interleukin-2); MESNA (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
CLINICAL TRIAL 23549
A Phase 1/1b Study of VET3-TGI Administered Alone and in Combination with Atezolizumab in Patients with Advanced Solid Tumors
Condition: Thoracic
Intervention: Atezolizumab (Tecentriq); VET3-TGI ()
CLINICAL TRIAL 23636
A Phase 1, First-in-Human, Dose Escalation and Expansion Study to Evaluate the Safety and Tolerability of XmAb541 in Advanced Solid Tumors
Condition: Gynecological Tumor
Intervention: XmAb541 ()
CLINICAL TRIAL 23645
A Phase 1 Study of XB628 in Participants With Recurrent Advanced or Metastatic Solid Tumors
Condition: Multiple
Intervention: XB628 ()
CLINICAL TRIAL 23697
A Phase 1/1b, Open-label, Multicenter, First-in-human Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of VVD-159642, a RAS-PI3KA Inhibitor, as a Single Agent and in Combination in Participants With Advanced Solid Tumors
Condition: Multiple
Intervention: AMG 510 (Sotorasib); GSK1120212 (Trametinib); Olomorasib (); Sotorasib (); Trametinib (); VVD-159642 ()